Theralase® Technologies Inc. announced that Virginia Urology ("VU") has received site Institutional Review Board ("IRB") approval to commence a pivotal phase I Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study to enroll and treat patients with Bacil us Calmette Guerin("BCG")-Unresponsive Carcinoma In-Situ ("CIS") or are intolerant to BCG Therapy ("Study I "). Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. VU is the first site to receive both central and local site IRB approval. There are 5 additional US clinical study sites that have received central IRB approval and are expected to receive local IRB approval in first quarter 2021. VU has a long history of providing quality care to the Greater Richmond area since 1929. VU is comprised of 6 locations throughout the Greater Richmond area with over 55 board-certified physicians that span nearly every discipline within the field of urology. Because VU consists of diverse medical professionals, they are able to provide the latest technologies with a mission of providing the best possible care for each patient.